Sign up Australia
Proactive Investors - Run By Investors For Investors

GI Dynamics, Inc reveals positive data for obesity treatment device

Patients receiving the treatment achieved 10% decrease in BMI.
GI Dynamics, Inc reveals positive data for obesity treatment device
Obesity has a significant effect on morbidity for adolescents

GI Dynamics, Inc (ASX:GID) has completed the enrolment and received positive preliminary results in the first clinical trial evaluating its EndoBarrier device for obese adolescents.

The company’ share price has doubled since the start of 2017, last trading at $0.046.

EndoBarrier is an endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity.

GI Dynamics conducted the study at the University Children’s Hospital (UCH) in Ljubljana, Slovenia.

The study was designed to determine the efficacy and safety of the EndoBarrier treatment for up to one year in morbidly obese adolescents.

Preliminary data show that patients who received the treatment saw an average of 10% decrease in body mass index (BMI) and metabolic improvements.

EndoBarrier demonstrated therapeutic benefit in treating prediabetes, as blood sugar levels were reduced by 6%.

Most notable was the 49% improvement in HOMA-IR (Homeostatic Model Assessment), a critical measure of insulin resistance and beta-cell function.

EndoBarrier demonstrated an acceptable safety profile, with all study subjects completing treatment to the intended twelve-month implant duration.

Obesity and its complications have a significant effect on morbidity and mortality for adolescents.

Standard treatment-based diets and cognitive therapy have limited effects. Surgical bariatric procedures are non-reversible and permanently alter certain metabolic functions.

EndoBarrier is less invasive than surgery and can be inserted in a quick outpatient endoscopic procedure that patients are likely to find more acceptable.

GI Dynamics is well funded with a cash balance of $8.3 million as at 31 December 2016.

Register here to be notified of future . Company articles
View full . profile View Profile

Proactive Investors Australia Timeline

June 13 2017

Related Articles

February 21 2017
One particular development of note is Cello Pulsar, a social media analytics tool that has, according to the experts, the potential to be a real winner.
October 18 2016
Geographical expansion, product innovation and strategic partnerships continue to be well executed, said house broker finnCap
White board with marketing ideas
March 14 2017
There was a bit of a wobble in the run-up to the Brexit vote and shortly after it, but the group's 'buy, build & grow' strategy is taking shape

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use